The Return of Fast-Tracked mRNA Vaccines

Over the past several weeks, federal officials have announced plans to accelerate the development and review of next-generation vaccines, including those built on mRNA technology. Supporters argue that modern manufacturing methods can shorten development timelines, reduce production costs, and respond more quickly when viruses change.

From a manufacturing perspective, those claims are largely accurate. Unlike traditional influenza vaccines, which often require months of growing viruses in eggs or cell cultures, mRNA vaccines are designed from a genetic sequence. Once researchers know the sequence of a viral protein they want the immune system to recognize, the mRNA can be synthesized relatively quickly using a standardized production process.

The result is a platform that can be updated much faster than conventional vaccine manufacturing.

For many researchers, this speed represents one of the greatest advantages of mRNA technology. Others question whether a technology that instructs human cells to produce viral proteins should be rushed through development. The technology was introduced under emergency conditions with unprecedented speed. Years later, rather than slowing down to reflect on what we've learned, policymakers are discussing ways to make the next generation of mRNA vaccines even faster and less expensive to produce.

What Makes mRNA Different?

Traditional vaccines typically introduce either an inactivated virus, a weakened virus, or purified viral proteins into the body. The immune system recognizes those foreign proteins and develops immune memory.

mRNA vaccines* take a different approach.

Instead of delivering the protein itself, they deliver messenger RNA—a temporary genetic blueprint that instructs certain cells to manufacture a viral protein after vaccination.

Once inside the cell's cytoplasm, ribosomes read the modified mRNA and translate its genetic instructions into the encoded viral protein. The immune system then recognizes that protein as foreign and mounts an immune response.

In other words, rather than manufacturing the viral protein in a laboratory and injecting it into the body, the manufacturing process begins inside the recipient. The vaccine relies on the body's own cells to become temporary protein factories, directing them to produce a viral protein that healthy human cells would not ordinarily produce unless infected with the virus.

Foreign Proteins and the Immune System

The immune system is designed to recognize proteins that do not normally belong in the body. When it encounters one, it responds, which is exactly what vaccines are intended to stimulate.

The question researchers continue to study is not whether the immune system recognizes these proteins—it does—but rather whether the amount produced, the duration of production, the tissues involved, and individual biological differences influence the overall response.

Areas of active scientific investigation:

• How long does vaccine-derived protein production continue in different individuals?
• Which tissues produce the protein after vaccination?
• How much variation exists between individuals?
• How long does vaccine mRNA remain detectable?
• Could repeated exposure produce different immune responses over time?

The discussion highlights another important question:
How much long-term evidence should society expect before rapidly expanding a new medical platform into additional vaccines and therapies?

A Different Biological Question

Traditional vaccines introduce the antigen into the body. The immune system responds, and the antigen is eventually cleared. mRNA vaccines deliver the genetic instructions for making the antigen, which means different people may produce different amounts of the viral protein after receiving the same vaccine.

Researchers continue to study how much protein is produced, how long production continues, and whether those answers differ from one person to another. Unlike a conventional vaccine, where the manufacturer controls the amount of protein placed into each dose, mRNA vaccines rely on each recipient's cells to manufacture the protein after injection.

Where Is the Protein Produced?

Another area of ongoing research involves bio-distribution. After injection, lipid nanoparticles are intended to deliver modified mRNA into cells. Researchers are still studying where those particles travel, which tissues take them up, and where the encoded protein is ultimately produced.

Expansion Beyond COVID-19

COVID-19 was never intended to be the end of mRNA technology. From the beginning, researchers viewed it as proof of concept for a much larger platform. Today, modified mRNA technology is being developed for influenza, RSV, personalized cancer treatments, and numerous other infectious and noninfectious diseases.

So, the question is no longer whether mRNA technology will continue to be used, it will. The question is how rapidly it should expand while important biological questions are still being investigated.

*The "m" in mRNA stands for messenger RNA. However, the mRNA used in the Pfizer-BioNTech and Moderna COVID-19 vaccines is modified messenger RNA (modRNA). It contains laboratory-engineered chemical modifications, including the substitution of N1-methylpseudouridine for much of the uridine, to improve stability, reduce innate immune activation, and increase protein production. Thus, while commonly referred to as "mRNA vaccines," they use a modified form of messenger RNA rather than naturally occurring cellular mRNA.